nimotuzumab

Home
Ligands
nimotuzumab

GtoPdb Ligand ID: 7988

Synonyms: h-R3 | THERACIM® | Theraloc®

nimotuzumab is an approved drug (China, India, others (2014))

Comment: Nimotuzumab is a monoclonal antibody directed agianst the epidermal growth factor receptor (EGFR), being developed as an antineoplastic agent.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis using the light chain variable region of nimotuzumab provides a 100% match with sequence 35 from patent US6506883 [1].

Biosimilar drug: Biocon Limited are developing BIOMAb-EGFR^TM as a nimotuzumab biosimilar

No information available.

No information available.

Summary of Clinical Use
Nimotuzumab has been approved in some countries (including China, India and the Philippines) for the treatment of squamous cell carcinomas of the head and neck. In 2004 the EMA granted orphan designation for nimotuzumab as a treatment for high grade glioma and pancreatic cancer, however in 2007 the drug's manufacturer requested withdrawl of its application for EU-wide marketing authorisation. ClinicalTrials.gov has many active trials of this agent in its registry (as of September 2019). Click here to link to ClinicalTrials.gov's full list of nimotuzumab studies.

Summary of Clinical Use

Nimotuzumab has been approved in some countries (including China, India and the Philippines) for the treatment of squamous cell carcinomas of the head and neck. In 2004 the EMA granted orphan designation for nimotuzumab as a treatment for high grade glioma and pancreatic cancer, however in 2007 the drug's manufacturer requested withdrawl of its application for EU-wide marketing authorisation. ClinicalTrials.gov has many active trials of this agent in its registry (as of September 2019). Click here to link to ClinicalTrials.gov's full list of nimotuzumab studies.

Mechanism Of Action and Pharmacodynamic Effects
EGFR is expressed on the surface of some tumour cells. When activated, EGFR helps the tumour cells grow, multiply and spread. By blocking EGFR, nimotuzumab is expected to slow down cancer progression.

Mechanism Of Action and Pharmacodynamic Effects

EGFR is expressed on the surface of some tumour cells. When activated, EGFR helps the tumour cells grow, multiply and spread. By blocking EGFR, nimotuzumab is expected to slow down cancer progression.